Product Description
Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It's a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs. It depends on the type of cancer you have as to which drugs you have it with. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/oxaliplatin-eloxatin)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Colorectal Cancer | Oncology Unspecified
Known Adverse Events: Stomatitis | Anemia | Neutropenia | Diarrhea
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Russia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 119
Highest Development Phases
Phase 3: Adenocarcinoma|Biliary Tract Cancer|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Esophageal Cancer|Gastrointestinal Cancer|Hodgkin Lymphoma|Liver Cancer|Lymphoma, Non-Hodgkin|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Peritoneal Cancer
Phase 2: Anal Cancer|Bladder Cancer|Breast Cancer|Chemical and Drug Induced Liver Injury|Cholangiocarcinoma|Digestive System Cancer|Esophageal Diseases|Hepatic Veno-Occlusive Disease|Hepatocellular Carcinoma|Intestinal Diseases|Squamous Cell Carcinoma|Stomach Diseases
Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STEREOPAC-001 | P2 |
Unknown Status |
Adenocarcinoma|Pancreatic Cancer |
2032-10-01 |
|
| 2023-509814-12-00 | P2 |
Unknown Status |
Colorectal Cancer |
2031-03-31 |
|
| ACO/ARO/AIO-18.2 | P3 |
Recruiting |
Colorectal Cancer |
2030-08-01 |
|
| MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |